What amount sold does Thunder Biotech, Inc. report in Form D filings?

The latest linked filings report $24.5M sold across 7 identified offering(s). 0 unlinked amendment(s) are excluded; 0 offering(s) have no reported amount sold. This is not verified lifetime funding or money raised during a specific period.

When was Thunder Biotech, Inc.'s most recent SEC filing?

Thunder Biotech, Inc.'s most recent Form D filing was on 2024-02-26.

How many investors does Thunder Biotech, Inc. have?

The most recent Form D filing lists 2 investor(s).

What type of securities does Thunder Biotech, Inc. offer?

Thunder Biotech, Inc.'s SEC Form D filings indicate debt offerings.

Thunder Biotech, Inc.

CIK: 0001707315·Biotechnology·PROVO, UT·Corporation

Reported Sold

$24,514,789

Total Filings

Identified Offerings

Last Filed

Feb 26, 2024

Employees

—

Reported sold uses the latest linked filing for each identified offering; it is not verified lifetime funding. SPV filings are shown separately.

About

Company in Biotechnology industry

SEC EDGAR

Offering filing timeline

Feb 26, 2024Form D — New notice

Reported sold: $100,000 · Target: $2,500,000

Rule 506(b)·2 investors

Oct 17, 2022Form D/A — Amendment

Reported sold: $1,000,000 · Target: $20,000,000

Rule 506(b)·1 investor

Oct 17, 2022Form D/A — Amendment

Reported sold: $1,000,000 · Target: $20,000,000

Rule 506(b)·1 investor

Oct 14, 2022Form D — New notice

Reported sold: $1,000,000 · Target: $20,000,000

Rule 506(b)·1 investor

Oct 11, 2022Form D — New notice

Reported sold: $4,020,000 · Target: $15,000,000

Rule 506(b)·14 investors

Aug 22, 2022Form D — New notice

Reported sold: $9,979,274 · Target: $10,000,000

Rule 506(b)·52 investors

Aug 22, 2022Form D — New notice

Reported sold: $8,320,515 · Target: $10,000,000

Rule 506(b)·40 investors

Nov 6, 2017Form D — New notice

Reported sold: $325,000 · Target: $18,000,000

Rule 506(b)·3 investors

May 23, 2017Form D — New notice

Reported sold: $770,000 · Target: $2,000,000

Rule 506(b)·10 investors

Fundraising Profile

Exemptions

Rule 506(b)

Investors in latest filing

Revenue Range

Decline to Disclose

Reported commissions across identified offerings

$800,000

Amendment Rate

22%

Latest reported sold across 7 identified offerings

$24,514,789

Uses the latest linked filing for each offering. This is not a measure of money raised in the last year or verified lifetime funding.

Key People

James Burgess

Related Person

Appears on 7 filings

Kim L. O'Neill

Related Person

Appears on 6 filings

Kent A. Misener

Related Person

Appears on 6 filings

Steven A. Tanner

Related Person

Appears on 6 filings

Morris Linton

Related Person

Appears on 6 filings

D. Brent Israelsen

Related Person

Appears on 3 filings

Robert P.K. Mooney

Related Person

Appears on 3 filings

J. Anthony Antonelli

Related Person

Appears on 3 filings

Filing History

Date	Type	Offering target	Reported sold	Investors
Feb 26, 2024	New	$2,500,000	$100,000	2
Oct 17, 2022	Amendment	$20,000,000	$1,000,000	1
Oct 17, 2022	Amendment	$20,000,000	$1,000,000	1
Oct 14, 2022	New	$20,000,000	$1,000,000	1
Oct 11, 2022	New	$15,000,000	$4,020,000	14
Aug 22, 2022	New	$10,000,000	$8,320,515	40
Aug 22, 2022	New	$10,000,000	$9,979,274	52
Nov 6, 2017	New	$18,000,000	$325,000	3
May 23, 2017	New	$2,000,000	$770,000	10

Filing History

Amendment insights

Loading amendment history…

Comparable issuers

Matched on reported industry and issuer type, then ranked by business location, offering target, and recency. These are filing comparables, not verified business competitors.

Accufy Diagnostics, Inc.

Biotechnology

Offering target: $2,000,000

Filed Oct 28, 2026